Seer, Inc. announced on November 4, 2021, David Singer notified the board of his intent to resign as a director, effective as of November 8, 2021. Singer?s decision was not the result of any dispute or disagreement with the company on any matter relating to the company?s operations, policies or practices. The board appointed director Dipchand (Deep) Nishar to replace Singer as a member of the audit committee.
Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products that open a new gateway to the proteome. Its product, the Proteograph Product Suite (Proteograph), leverages its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access to the proteome. The Proteograph Product Suite is an integrated solution that includes consumables, an automation instrument and software. Its proprietary engineered NPs provide unbiased sampling of intact proteins across the dynamic range of the proteome, capturing molecular information at the peptide-level, including protein variants. It is focused on driving the adoption of the Proteograph by customers in the proteomics and genomics markets. The Proteograph Product Suite is an integrated solution consisting of consumables, an automation instrument, and software to perform biased, deep proteomic analysis at scale in a matter of hours.
SEER, INC. 
